Click here to view CSRO's latest news.
posted: December 18, 2020 to CSRO News
posted: December 11, 2020 to CSRO News
Today, the Supreme Court of the United States unanimously upheld Arkansas’ Pharmacy Benefit Manager (PBM) law in the Rutledge V. PCMA case.
posted: October 16, 2020 to Federal
Accumulator adjustment programs are a utilization management tool that prevent the value of co-pay assistance from applying to a patient’s deductible, leaving patients vulnerable to high out-of-pocket expenses when the value of their co-pay assistance runs out.
posted: October 2, 2020 to Federal
The COVID-19 pandemic has substantially disrupted many private medical practices across the country. New operational expenses, reduced service and revenues, and other variables have threatened the viability of many of these practices. Rheumatology has not remained unscathed.
posted: September 18, 2020 to CSRO News
CSRO hosted its annual State Society Advocacy Conference. While this was the 8th iteration of the SSAC, it also marked the first time the conference occurred in a virtual format. Despite the venue changed forced by the pandemic, CSRO was pleased to present an excellent program with strong attendance.
posted: August 21, 2020 to CSRO News
Accumulator adjustment programs are a newly emergent utilization management tool used by PBMs, that have grown increasingly prevalent over the past few years. The programs prevent the value of co-pay assistance from applying to a patient’s deductible, leaving patients vulnerable to high out-of-pocket expenses when the value of their co-pay assistance runs out.
posted: July 24, 2020 to CSRO News
CSRO Opposes BCBST White-bagging Policy
posted: June 26, 2020 to Federal
After announcing plans to distribute an addition $15 billion to participants in state Medicaid and CHIP programs, the Department of Health and Human Services issued a number of clarifications for providers who received funds from the general distribution fund.
posted: June 12, 2020 to CSRO News
Late last year, Blue Cross Blue Shield of Tennessee (BCBST) announced a sweeping policy that would mandate the use of a white-bagging acquisition system for a substantial number of covered lives in Tennessee. The policy would have, in effect, disallowed the use of buy and bill.
posted: May 29, 2020 to State
For Louisianans with chronic health conditions, it is important to get timely access to the medications and treatments they need. We must ensure that doctors and their patients, not a one-size-fits-all insurance policy, make the right decision for the right treatment at the right time.
posted: April 30, 2020 to Federal
In response to rapidly evolving circumstances surrounding the COVID-19 pandemic, CMS has made numerous interim revisions to its policies. These changes are designed to streamline patient access to care during the pandemic and large scale social distancing.
posted: April 21, 2020 to State
On Tuesday, March 24th South Dakota Governor, Kristi Noem, signed SB 155 into law as S.J. 588. The law provides sorely needed reforms to the step-therapy process for patients and providers in South Dakota.
posted: April 8, 2020 to CSRO News, Federal
CSRO is imploring its membership to utilize the COVID-19 Global Rheumatology Alliance Healthcare Provider Entered Registry during the unprecedented era of global pandemic.
posted: March 25, 2020 to CSRO News
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration co-sponsored a public workshop focusing on promoting competition in biologics markets. The workshop was held at the FDA’s White Oak Campus in Silver Spring, Maryland and was also viewable via webcast.
posted: March 17, 2020 to CSRO News
On March 7th, 2020, the CSRO held its annual Fellows Conference in San Francisco. Attending fellows were introduced to a network of experienced physicians that they can tap into as they prepare for their futures.
posted: March 10, 2020 to Policy Update
With the turning of the decade I have recently been reflecting on CSRO’s growth and achievements over the course of the past ten years.
posted: February 12, 2020 to CSRO News
Following a press release issued by BlueCross BlueShield of Tennessee attacking the Coalition of State Rheumatology Organizations for exposing a policy that will prove to harmful to patients, Dr. Madeline Feldman, CSRO’s President, issued this statement.
posted: February 10, 2020 to CSRO News
CSRO has developed a new legislative map tool which serves as a clearinghouse of both active bills and enacted legislation.
posted: January 29, 2020 to CSRO News, Federal
CSRO physicians are voicing concern for patients who will fall victim of a dangerous new prescription policy. New requirements from BlueCross BlueShield (BCBS) of Tennessee, which may be a bellwether for other insurers, are reversing the trend providers have achieved in keeping prices down for physician administered medications.
posted: December 19, 2019 to State
This week, Jackie Toledo, a member of the Florida House of Representatives, filed legislation that would lower prescription drug prices for patients and protect small pharmacy owners by regulating pharmacy benefit managers (PBMs). The passage of her bill, HB 961, would be a monumental achievement in the crusade for PBM transparency.
posted: November 20, 2019 to CSRO News, State
CSRO President, Madelaine Feldman, MD, FACR, Testifies Before the Florida Senate Health Policy Committee, Explaining PBM Practices and How They are Hurting Florida’s Patients
posted: November 20, 2019 to CSRO News
Earlier this month, CSRO’s officers and board of directors traveled to Atlanta, Georgia to attend the American College of Rheumatology’s annual meeting.
posted: October 17, 2019 to State
For the last couple of years, the issue of Pharmacy Benefit Managers (PBMs) and their impact on the health care system has been a topic of much concern in both the state of Ohio and the nation as a whole.
posted: September 20, 2019 to CSRO News
CSRO’s 2019 SSAC conference brought rheumatology advocates together from across the country to inspire action on issues affecting the practice of rheumatology.
posted: August 30, 2019 to CSRO News, Policy Update
As CSRO prepares for the 2019 State Society Advocacy Conference (SSAC), healthcare has moved to the fore of national political conversations, providing the rheumatology profession much to discuss. Since its inception, CSRO’s guiding mission has been to ensure excellence in the field of rheumatology for rheumatologists and the patients that we take care of.
posted: July 12, 2019 to Federal
On July 11th, the White House announced that it was withdrawing its proposal to reformulate the way drug rebates work in federal programs.
posted: June 14, 2019 to Federal
The Centers for Medicare and Medicaid (CMS) published its “Medicare Advantage and Part D Drug Pricing Final Rule” in May which seeks to increase drug pricing transparency, lower prescription drug costs, and improve patient medication adherence.
posted: May 30, 2019 to CSRO News, Federal
Last week, the House Energy and Commerce Subcommittee on Health held a hearing entitled: “Improving Drug Pricing Transparency and Lowering Prices for American Consumers.” CSRO President, Dr. Madelaine Feldman, was invited to represent the Alliance for Specialty Medicine and deliver testimony at the hearing.
posted: May 24, 2019 to Federal
Last week, the FDA released its long anticipated final guidance for industry on “Considerations in Demonstrating Interchangeability with a Reference Product.”
posted: April 9, 2019 to CSRO News, Federal
The gridlock immobilizing Congress has slowed the progress of health care legislation significantly, but it has not stopped key Federal agencies from proposing and implementing policies that have a far reaching impact on the practice of rheumatology.
posted: April 8, 2019 to CSRO News, Federal
The Coalition of State Rheumatology Organizations (CSRO) recently submitted comments on the Department of Health and Human Services (HHS) proposed rule amending the Federal anti-kickback statute.
posted: March 11, 2019 to State
CSRO, in partnership with the Wisconsin Step Therapy Coalition is taking the lead on step therapy reform in the state.
posted: February 28, 2019 to CSRO News, Federal
CSRO Board Member, Robert Levin, participated in the Healthcare Policy podcast on February 18 to discuss federal prescription drug pricing reform. In his capacity as a practicing physician, and president the Alliance for Transparent and Affordable Prescriptions, Dr. Levin provided expert testimony on drug pricing reform proposals and how the drug supply chain works.
posted: February 14, 2019 to CSRO News
On February 9, 2019, the CSRO held its annual Fellows Conference in San Francisco, complete with a number of presentations on topics that surround today’s Rheumatologist.
posted: February 13, 2019 to State
Non-medical switching is a strategy used by health plans to reduce expenses by switching the prescription for a stable patient to a “preferred” drug — for reasons unrelated to the patients’ well-being and in some cases without warning.
posted: January 29, 2019 to State
A new law in Illinois ensures that commercial health plans deliver on policies they market and sell to Illinoisans. Prior to January 1st of this year, insurers in Illinois could change prescription drug coverage on a patient at any point during the year, and while patients were still locked into their plan. This practice is referred to as “non-medical switching” and can have serious negative health effects for patients.
posted: January 10, 2019 to Federal
Without a doubt, lowering list-prices for prescription drugs was a national focus in 2018. Coupled with numerous advocacy organizations bringing increased awareness to Pharmacy Benefit Managers’ (PBMs) unfair practices, and their effect on drug prices, several reforms have sparked across the U.S. and are expected to increase in intensity in 2019.
posted: January 3, 2019 to CSRO News, Policy Update
As the new year begins, I would like to reflect on the tremendous organizational successes that CSRO achieved in 2018. Over the past couple of years, CSRO made a commitment to deepening its ties with the societies it represents, and its allied patient and provider organizations. This year CSRO traveled to 20 state society meetings to bring increased awareness to the issues impacting practicing rheumatologists and patients in the U.S.
posted: January 3, 2019 to CSRO News, Federal
Prior to commenting on the proposed International Pricing Index Model (IPI) for Part B drugs, CSRO leadership met with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma to convey rheumatology's perspective.
posted: December 21, 2018 to CSRO News
Accumulator Adjustment Programs have become an increasingly prevalent issue since CSRO was first made aware of them in late 2017. Since then, the programs have been progressively crossing over from the employer to commercial space.
posted: November 29, 2018 to State
CSRO has been fielding reports from physicians around the states who have found that their patients are no longer able to access their prescribed treatment. Some hospital systems are no longer carrying biologic originator products, meaning that patients must find an alternative site of care.
posted: November 14, 2018 to Federal
This week, Express Scripts announced that it would provide clients with the ability to opt for its new National Preferred Flex Formulary Design. As opposed to favoring drugs that garner the most rebate dollars, the new benefit design intends to favor drugs that have lower list prices to begin with.
posted: November 1, 2018 to CSRO News, State
On Monday, October 22nd, CSRO hosted a breakfast for state rheumatology society leaders present at the ACR. Attendees had the opportunity to learn more about emergent patient access issues, CSRO’s plans for 2019, and hear from a speaker who discussed implementation and compliance issues with existing patient access laws.
posted: October 30, 2018 to CSRO News, Federal
Last week, CSRO’s Past President and National Advocacy Chair, Michael Schweitz, MD, participated in one-on-one discussions with Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma and Special Advisor to the Administrator Jeet Guram, MD, to discuss details about the Trump Administration’s potential International Pricing Index Model for Medicare Part B Drugs.
posted: September 27, 2018 to CSRO News
The CSRO has been deeply concerned about the expanded implementation of a new utilization management tool known as co-pay accumulator programs over the course of 2018.
posted: September 25, 2018 to CSRO News
The CSRO was excited to host many members of the state rheumatology societies and other partners in Chicago on Saturday, September 15th for the annual State Society Advocacy Conference (SSAC).
posted: August 28, 2018 to CSRO News, Policy Update
As the last of the 2018 regular sessions wind down across the states, CSRO is happy to report that the year to date has been marked by a number of successes on the patient access front.
posted: August 28, 2018 to State
On Friday, August 24th, Illinois’ Governor signed HB4146 into law, providing patients much needed protections from non-medical switching.
posted: August 8, 2018 to CSRO News, Federal
Members of CSRO’s executive board recently met with CMS to discuss Part B and D drug pricing. Doctors Michael Schweitz, Madelaine Feldman, Greg Schimizzi traveled to D.C. to present CSRO’s feedback on recent proposals and provide rheumatology’s perspective on the programs.
posted: August 6, 2018 to CSRO News, State
Each year state legislators from across the country congregate to discuss innovative solutions that can be implemented to solve problems faced in common by various state legislatures.
posted: July 19, 2018 to State
Over the course of the past year, interchangeable biosimilar substitution laws with physician communication provisions have continued to find enormous success in the states.
posted: July 16, 2018 to CSRO News, Federal
CSRO has submitted their comments regarding the Request for Information (RFI) by the Department of Health and Human Services.
posted: July 16, 2018 to CSRO News, State
CSRO staff was pleased to attend the 2018 Florida Society of Rheumatology Conference in Orlando, Florida.
posted: June 29, 2018 to State
Late in Maine’s 2018 session, the legislature passed two separate patient protections measures of benefit to patients battling chronic illnesses.
posted: May 21, 2018 to State
On Friday, May 15th, Governor Mark Dayton of Minnesota signed HF3196 into law providing important patient protections to Minnesota patients.
posted: May 14, 2018 to State
HB4146, a bill that protects patients from mid-year formulary changes, has been making steady progress in the Illinois legislature this year. After passing the House, it was assigned to the Special Committee of Medicaid Managed Care, where it was heard in a subject matter hearing on Wednesday, May 9th.
posted: May 1, 2018 to State
Pending the Governor’s signature, passage of the law would cap a multi-year effort to improve future uptake of interchangeable biosimilars that faced numerous obstacles.
posted: March 23, 2018 to State
​Last weekend CSRO Vice President, Dr. Madelaine Feldman, traveled to the Wisconsin Rheumatology Association’s annual meeting to represent CSRO, and educate attendees on the role that Pharmacy Benefit Managers (PBMs) play in inflating the price of prescription drugs.
posted: March 9, 2018 to State
In late February, Michigan enacted a biosimilar substitution law that promises to improve uptake of biosimilars, while maintaining appropriate patient protections by requiring notification of substitutions to prescribers.
posted: February 14, 2018 to State
The New Mexico state legislature overwhelmingly approved SB 11, a bill that promises to reform the use of step-therapy protocols by insurers.
posted: February 8, 2018 to CSRO News
The CSRO is pleased to announce that its nominee, Kent “Kwas” Huston, MD, from the Kansas City Physicians Partners, has been selected to serve on the Centers for Medicare & Medicaid Services (CMS) Technical Expert Panel (TEP).
posted: January 30, 2018 to CSRO News, Policy Update
The CSRO closed out 2017 with legislative and regulatory victories across the country that positively affected the lives of our patients and practices.
posted: January 18, 2018 to State
On Tuesday, January 16th CSRO staff joined allies in Albany, New York to educate lawmakers on utilization management, and pending legislation that promises to improve patient access and continuity of care.
posted: December 14, 2017 to CSRO News, Federal
CSRO Vice President, Dr. Madelaine Feldman recently presented on Pharmacy Benefit Managers and utilization management tools at the Board of Hispanic Caucus Chairs meeting in Las Vegas, Nevada.
posted: December 14, 2017 to State
Dr. Robert Levin, President of the Florida Society of Rheumatology recently testified to the House Health Innovation Subcommittee on the role that Pharmacy Benefit Managers have played in inflating the cost of prescription drugs.
posted: December 11, 2017 to CSRO News, State
On Tuesday, December 5th, CSRO hosted a reception for Florida legislators in partnership with the Florida Society of Rheumatology (FSR). An array of stakeholders including patients and physicians met and spoke with legislators that are deeply invested in CSRO and FSR’s shared priorities.
posted: December 7, 2017 to Federal
To date, the U.S. Food and Drug Administration (FDA) has approved seven biosimilars, and some are already on the market. As the biosimilars market continues to grow, there are still a lot of questions from both patients and physicians about these important new treatment options.
posted: November 29, 2017 to CSRO News, Federal
The CSRO has submitted comments to CMS expressing concerns with their intent to establish a national benchmark plan standard for prescription drugs in future years.
posted: November 20, 2017 to Federal
The CSRO has responded to a request for information (RFI) from the Innovation Center as the federal agency plans for a new direction. The comments submitted focus on specific issues that uniquely impact practicing rheumatologists and the patients they serve.
posted: October 5, 2017 to CSRO News, Federal
Dr. Madelaine Feldman traveled to Washington D.C. recently to attend the Patient and Health Advocacy Bio Summit.
posted: September 27, 2017 to CSRO News
As patient and physician advocates, the Coalition of State Rheumatology Organizations (CSRO) actively monitors changes that affect physician’s ability to effectively treat their patients and operate their practices.
posted: September 22, 2017 to CSRO News, State
On September 20, 2017, Dr. Joshua Stolow traveled to Utah to testify on the necessity of patient protection legislation addressing step therapy protocols.
posted: September 13, 2017 to CSRO News, Federal
As patient and physician advocates, the CSRO actively monitors regulatory changes that affect physician’s ability to effectively treat their patients and operate their practices. As such, the CSRO took note of and discussed revisions proposed by the Center for Medicare and Medicaid Services for 2018.
posted: September 6, 2017 to State
Nevada Governor Brian Sandoval signed a landmark drug transparency law in June that focuses on diabetes drug manufacturers and their intermediaries more broadly.
posted: August 30, 2017 to Federal
The expansive list of actors involved in delivering prescription drugs to patients substantially inhibits patients from making fully informed treatment and purchasing decisions.
posted: August 21, 2017 to State
Patients and physicians in Texas won a major victory against the step-therapy protocols instituted by insurance companies this spring with the passage of Senate Bill 680.
posted: August 21, 2017 to CSRO News, Federal
The Coalition of State Rheumatology Organizations (CSRO) and several state societies submitted comments to CMS today in response to the CY 2018 Updates to the Quality Payment Program.
posted: August 11, 2017 to CSRO News, Federal
As patients, providers, and politicians alike look for answers to the soaring cost of prescription drugs, some patients have taken matters into their own hands. A series of lawsuits have popped up across the country targeting pharmacies and their relationship to pharmacy benefit managers.
posted: June 29, 2017 to Federal, State
The FDA has released its highly anticipated but long delayed interchangeability guidelines, and the market seems primed for new developments.
posted: June 28, 2017 to Federal
At the AMA’s Annual House of Delegate Meeting, hundreds of medical professionals gathered to discuss and address a wide range of healthcare issues, including the opioid crisis, physician burnout, regulating physician assistants and advanced practice registered nurses, and of course, healthcare reform and drug pricing.
posted: June 27, 2017 to Federal, State
The Food and Drug Administration’s guidelines for biosimilar interchangeability, released in January 2017, have come under renewed focus with concerns about patients being switched onto biosimilars by insurers without consultation with their physicians.
posted: June 23, 2017 to State
California’s Assembly Bill 315, which takes aim at Pharmacy Benefit Managers (PBMs), recently cleared the Assembly floor, and is now headed to the Senate for consideration.
posted: June 20, 2017 to State
The Florida Society of Rheumatology, New York State Rheumatology Society, and California Rheumatology Alliance today became the newest members of the Alliance for Transparent & Affordable Prescriptions (ATAP), a new coalition of provider and patient groups concerned about the role of pharmacy benefit managers (PBMs) in driving up drug costs.
posted: June 16, 2017 to Federal
Despite intractable differences between the parties on healthcare policy, the Senate’s Health, Education, Labor, and Pensions Committee (HELP) convened a hearing this week to frame future efforts in combating high drug prices.
posted: June 15, 2017 to State
The Atlantic recently concluded its policy roundtable on biosimilars June 7th, with the third and final installment titled: “The Next Drugs: An Atlantic Policy Update on Biosimilars.”
posted: June 13, 2017 to Federal
Health leaders today announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs) driving up drug costs.
posted: May 31, 2017 to State
Maryland became the 35th state to approve of regulations and access for biosimilar medicines.
posted: May 25, 2017 to State
Minnesota's Governor signed HF712 into law, a bill for biosimilars.
posted: May 24, 2017 to CSRO News, Policy Update
In this issue: President’s Message; States Stride Toward Addressing; Patient Access Legislation; State Maps on Step Therapy & Biosimilars; Fellows Assemble in San Francisco to Prepare for Next Step; The Alliance for Transparent & Affordable Prescriptions; The Rebate System; ARA: CSRO Vice President Presents on PBMs and the Rebate System; CSRO discusses Biosimilars, Drug Pricing, and PBMs with CRA; CSRO Promotes Advocacy at 2017 CCR Conference; CSRO Participates in 2nd Annual National Policy & Advocacy Summit; Save the Date
posted: May 24, 2017 to State
The CSRO is pleased to announce that Texas Governor Greg Abbott has officially signed step therapy bill SB 680 into law.
posted: May 15, 2017 to CSRO News, State
The CSRO is pleased to report that CSRO Vice President Madeleine Feldman, MD, FACR, presented at the Arkansas Rheumatology Association, giving attendees an inside look at rising drug prices and the hidden rebate system controlled by pharmacy benefit managers (PBMs).
posted: May 10, 2017 to State
Legislation that provides the substitution and regulation of biosimilars, LB481, was approved by Nebraska’s Unicameral Legislature on a vote of 47 – 0. The bill now goes to Governor Pete Ricketts for his expected signature.
posted: May 10, 2017 to State
The CSRO is happy to announce that SB 680, step therapy bill introduced in the Texas Senate on January 31, has passed both the Senate and the House and is now headed to Governor Greg Abbott’s desk.
posted: May 10, 2017 to State
The CSRO is very happy to announce that Iowa Governor Terry Branstad has officially signed HF 233, step therapy bill introduced in the Iowa House by Representative Joel Fry (R, 27th) on January 23, into law.
posted: May 1, 2017 to State
HB3438 was signed by South Carolina Governor Henry McMaster. In Nebraska, LB481, a bill for biosimilars access and regulation, was approved on first round debate.
posted: April 24, 2017 to State
Like other states across the country, efforts to address step therapy in Florida are underway and making great progress as key legislation continues to move forward.
posted: April 19, 2017 to State
On April 13, HB 2055 was signed by Governor Sam Brownback. It included critical patient safety rules that involved a communication within 5 business days from pharmacists to physicians about any biosimilar substitutions.
posted: April 18, 2017 to State
The CSRO is pleased to announce that HF 233, step therapy bill introduced in the Iowa House by Representative Joel Fry (R, 27th) on January 23, has passed both the House and the Senate and is now headed to Governor Terry Branstad’s desk.
posted: April 14, 2017 to State
The CSRO was delighted to join the California Rheumatology Alliance in an informal presentation on the effect of biosimilars on rheumatology, and an inside look at rising drug prices and the hidden rebate system controlled by pharmacy benefit managers (PBMs). The panel that presented included Dr. Greg Schmizzi on biosimilars, with Dr. Madelaine Feldman, Pharmacist Keith Bradbury, and Attorney David Balto on PBMs.
posted: April 13, 2017 to State
HB3438 has unanimously passed both legislative chambers in South Carolina, and awaits Governor Henry McMaster’s signature.
posted: April 7, 2017 to State
Governor Susana Martinez signed HB260, which provides important pathways for patient access to biologic medications, while also creating much needed safety rules that include a mandate that pharmacists must communicate to physicians about a biosimilar substitution within 5 days of its dispensing.
posted: April 4, 2017 to State
In Kansas, HB2055 has reached approval in the House and Senate and awaits the Governor’s signature. This bill provides important pathways for access to biologic medications.
posted: March 29, 2017 to CSRO News, Federal
Rheumatologists are at the forefront of innovative treatments for patients with complex autoimmune diseases such as rheumatoid arthritis.
posted: March 27, 2017 to Federal
Ever-increasing drug prices have recently been at the forefront of the healthcare debate in America, and a new bill introduced in Congress last week may be the important first step in shedding light on the intermediaries who play a huge yet largely unnoticed role in drug pricing: Pharmacy Benefit Managers (PBMs).
posted: March 21, 2017 to State
Montana and Iowa recently joined the now 28 states to provide pathways for access to Biosimilars, and create much needed patient safety rules, including guidelines for dispensing pharmacists to communicate to physicians about biosimilar substitutions.
posted: March 21, 2017 to CSRO News, Federal
As patient and physician advocates, we have been deeply involved in the debate surrounding implementation of the Biologics Price Competition and Innovation Act (BPCIA).
posted: March 17, 2017 to State
Like multiple other states across the country, Iowa is tackling step therapy reform this year and is making great progress as efforts continue to move forward.
posted: March 15, 2017 to State
It was another active week for step therapy legislation across the country; here are some highlights from New Mexico and Texas.
posted: March 14, 2017 to State
Iowa joined the 27 other states, including Puerto Rico, that have passed legislation to provide pathways for access to Biosimilars, and create much needed patient safety rules, including a guideline for pharmacists to communicate to physicians about a Biosimilar substitution within 5 business days of its dispensing.
posted: March 7, 2017 to CSRO News, State
At the beginning of this new year, a worrisome change took effect for patients with chronic illnesses across Minnesota. Many patients have just become aware that their current medical treatment will no longer be covered, which may have a serious impact on their health in 2017 and lead to consequences beyond.
posted: March 1, 2017 to CSRO News
On February 18, the CSRO held another successful Fellows Conference, complete with a host of interesting presentations on pertinent topics.
posted: February 24, 2017 to State
The State of Montana joined the 26 other states, including Puerto Rico, that have now passed legislation to provide pathways for access to Biosimilars, and create much needed patient safety rules...
posted: February 15, 2017 to State
Attempting to join the 26 other states that have enacted laws for Biosimilars and their dispensing, Nebraska’s Unicameral Legislature will hear LB481 in the Health and Human Services Committee.
posted: February 13, 2017 to State
Like multiple other states across the country, Oregon is tackling step therapy reform this year and has made great progress so far.
posted: February 13, 2017 to CSRO News, Policy Update
In this issue: President’s Message; Biosimilar Advocacy Update; New CSRO Advocacy Initiative; Step Therapy Advocacy Update; Non-Medical Switching Legislation; Save the Date
posted: February 10, 2017 to State
Legislation is being unveiled across the country to address Biosimilars, and create the pathways needed for pharmacists to dispense Biosimilar substitutions to patients, while communicating the substitution with the patient’s physician in a timely manner.
posted: February 10, 2017 to State
It was another active week for step therapy legislation across the country; here are some highlights from Ohio and Iowa.
posted: February 3, 2017 to CSRO News, State
This week was a big one for step therapy legislation, which moved forward in three key states.
posted: February 1, 2017 to State
A step therapy bill in Iowa received unanimous support from a House subcommittee will now be heard by the full House committee in the coming weeks.
